Globus Medical Inc (GMED): who owns it and who trades it
As of Nov 16, 2026, GMED insiders reported 13 open-market sales worth $16M and no purchases in the last 12 months, with 3% of the sale value made under pre-set 10b5-1 plans. The largest seller was James R Tobin (Director), with $5.4M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Globus Medical
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors and Congress mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns GMED
595 funds and institutions reported GMED shares worth $9.5B at the end of Q2 2026, about 89% of the company. The largest holder is BlackRock, Inc. with 8.0%.
Funds and institutions (13F) 89%Everyone else 11%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 10.81M | 7.96% | $854M | +3% |
| Jupiter Topco LLC | 8.20M | 6.04% | $648M | – |
| Vanguard Capital Management LLC | 5.11M | 3.76% | $404M | +1% |
| Vanguard Portfolio Management LLC | 4.99M | 3.68% | $395M | +2% |
| Invesco Ltd. | 4.31M | 3.17% | $341M | -0% |
| Kayne Anderson Rudnick Investment Management LLC | 4.28M | 3.15% | $338M | – |
| State Street Corp | 3.71M | 2.74% | $294M | +3% |
| Sculptor Capital LP | 3.00M | 2.21% | $237M | -2% |
| JPMorgan Chase & Co | 2.74M | 2.02% | $231M | – |
| Bank of Montreal | 2.43M | 1.79% | $192M | +5% |
| Alliancebernstein L.P. | 2.38M | 1.75% | $205M | +36% |
| Dimensional Fund Advisors LP | 2.37M | 1.75% | $187M | +34% |
| Geode Capital Management, LLC | 2.15M | 1.59% | $170M | +2% |
| Goldman Sachs Group Inc | 1.78M | 1.31% | $141M | +57% |
| Arrowstreet Capital, Limited Partnership | 1.72M | 1.26% | $136M | +88% |
| Boston Trust Walden Corp | 1.57M | 1.16% | $124M | +25% |
| Allspring Global Investments Holdings, LLC | 1.57M | 1.16% | $119M | +267% |
| Boston Partners | 1.55M | 1.15% | $123M | – |
| GW&K Investment Management, LLC | 1.45M | 1.07% | $115M | -3% |
| Geneva Capital Management LLC | 1.42M | 1.04% | $112M | -20% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, GMED insiders reported $0 of open-market purchases and $16M of sales. 3% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | James R Tobin | Director | Sale | 37,662 | $75.10 | $2.8M | Form 4 |
| Nov 10, 2026 | James R Tobin | Director | Sale | 4,004 | $75.68 | $303K | Form 4 |
| Nov 4, 2026 | Ann D Rhoads | Director | Sale plan | 5,000 | $85.00 | $425K | Form 4 |
| Sep 15, 2026 | James R Tobin | Director | Sale | 30,000 | $74.58 | $2.2M | Form 4 |
| Aug 18, 2026 | Stephen T Zarrilli | Director | Sale | 25,000 | $87.04 | $2.2M | Form 4 |
| Jun 5, 2026 | David D Davidar | Director | Sale | 25,000 | $80.76 | $2M | Form 4 |
| Feb 25, 2026 | Kelly Huller | Vice president | Sale | 20,000 | $94.50 | $1.9M | Form 4 |
| Feb 12, 2026 | Kelly Huller | Vice president | Sale | 10,000 | $87.67 | $877K | Form 4 |
| Jan 8, 2026 | Kyle Kline | CFO | Sale | 3,594 | $101.10 | $363K | Form 4 |
| Jan 8, 2026 | Leslie V Norwalk | Director | Sale | 2,000 | $101.10 | $202K | Form 4 |
| Dec 12, 2025 | Leslie V Norwalk | Director | Sale | 4,000 | $88.85 | $355K | Form 4 |
| Dec 1, 2025 | Kyle Kline | CFO | Sale | 18,542 | $90.00 | $1.7M | Form 4 |
| Nov 25, 2025 | Kelly Huller | Vice president | Sale | 7,500 | $90.00 | $675K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| James R Tobin | Director | – | $5.4M | Nov 10, 2026 |
| Kelly Huller | SVP, GC, Corporate Secretary | – | $3.4M | Feb 25, 2026 |
| Stephen T Zarrilli | Director | – | $2.2M | Aug 18, 2026 |
| Kyle Kline | Senior Vice President, CFO | – | $2M | Jan 8, 2026 |
| David D Davidar | Director | – | $2M | Jun 5, 2026 |
| Leslie V Norwalk | Director | – | $558K | Jan 8, 2026 |
| Ann D Rhoads | Director | – | $425K | Nov 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
GMED short interest
Moderate short interest. 7.0% of GMED shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 177%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.46M GMED shares were sold short, 7.0% of the shares outstanding, up 15.5% from the report before. At the average daily volume of 1.17M shares, buying them all back would take about 8.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.46M | 7.04% | +15% | 1.17M | 8.1 |
| Oct 15, 2026 | 8.19M | 6.10% | -3% | 1.50M | 5.5 |
| Sep 30, 2026 | 8.44M | 6.28% | +25% | 1.64M | 5.1 |
| Sep 15, 2026 | 6.77M | 5.04% | +2% | 1.47M | 4.6 |
| Aug 31, 2026 | 6.62M | 4.93% | -3% | 1.01M | 6.5 |
| Aug 14, 2026 | 6.80M | 5.07% | -1% | 1.72M | 4.0 |
| Jul 31, 2026 | 6.89M | 5.07% | -3% | 1.41M | 4.9 |
| Jul 15, 2026 | 7.07M | 5.21% | -5% | 2.02M | 3.5 |
| Jun 30, 2026 | 7.41M | 5.46% | +35% | 2.08M | 3.6 |
| Jun 15, 2026 | 5.47M | 4.03% | +40% | 1.60M | 3.4 |
| May 29, 2026 | 3.92M | 2.89% | +15% | 2.03M | 1.9 |
| May 15, 2026 | 3.41M | 2.52% | +9% | 2.11M | 1.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded GMED
Since Nov 17, 2024, 3 members of Congress reported 4 purchases and 3 sales of GMED. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Sep 3, 2026, reported Oct 12, 2026.
Purchases 4Sales 3
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Oct 12, 2026 | Report |
| Aug 19, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $15K–$50K | Self | Sep 10, 2026 | Report |
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Apr 7, 2026 | Report |
| Jul 10, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jun 24, 2025 | Lisa C. McClain (R-MI) | Partial sale | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jun 17, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Apr 9, 2025 | Josh Gottheimer (D-NJ) | Partial sale | $1K–$15K | Joint | May 14, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Globus Medical company events
Globus Medical filed 7 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026AnnouncementThe Company’s Board of Directors authorized the Company to repurchase an additional $500.0 million of its Class A common stock under its existing share repurchase program. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 4, 2026LeadershipGlobus Medical, Inc. held its 2026 Annual Meeting of Stockholders at which the Company’s stockholders approved an amendment to the Globus Medical, Inc. 2021 Equity Incentive Plan to increase the number of shares authorized thereunder by 1,000,000 (the Plan as amended by the 2021 Equity Incentive… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 23, 2026LeadershipJohn A. DeFord, Ph.D., a member of the Board of Directors of Globus Medical, Inc., informed the Company of his resignation from the Board effective immediately. Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Jan 7, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Globus Medical financials
Famous investors that hold GMED
5 of the 50 well-known investors we track reported holding GMED in their latest 13F filing. The largest position is Jeremy Grantham's, worth $31M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jeremy Grantham · GMO | Q3 2026 | 413,407 | $31M | 0.1% | +1% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 404,918 | $30.3M | 0.0% | +106% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 316,708 | $23.7M | 0.1% | -10% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 114,620 | $8.6M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 93,519 | $7M | 0.0% | +224% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named GMED in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 4.4% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 4.4% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 8.0% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 8.0% |
Questions about Globus Medical Inc (GMED) stock
Who owns the most GMED stock?
The largest reported owner of Globus Medical Inc (GMED) is BlackRock, Inc., with 8.0% of the company. In total, 595 funds and institutions reported holding GMED at the end of Q2 2026, together about 89% of the shares. See the largest owners.
Are GMED insiders buying or selling?
In the last 12 months, GMED insiders reported no open-market purchases and 13 sales worth $16M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in GMED?
As of Oct 30, 2026, 9.46M GMED shares were sold short, 7.0% of the shares outstanding, up 15.5% from the report before. At the average daily volume of 1.17M shares, buying them all back would take about 8.1 trading days (days to cover). See the history.
Have members of Congress traded GMED?
Yes. 3 members of Congress reported 4 purchases and 3 sales of GMED since Nov 17, 2024. The latest was reported on Oct 12, 2026. See the trades.
Which famous investors hold GMED?
5 of the 50 well-known investors we track reported GMED in their latest 13F filing, including Jeremy Grantham, Jim Simons, Ray Dalio. The largest position is worth $31M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.